Vivosim Labs Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Vivosim Labs Inc (VIVS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Vivosim Labs Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 226M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-35.7% annualized vs trailing 12 months), vs accelerating (+70.1%) for its tracked peer group.
- Growth: Vivosim Labs Inc generated -51.4% revenue growth year over year in Q1 2026, vs 274.4% for its competitors combined.
- Profitability: Its -7,433.3% net margin compares with -98.2% for the peer group.
- Scale: Vivosim Labs Inc ranks #154 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
- Peer revenue share: Vivosim Labs Inc accounted for 0.0% of combined revenue among its tracked peer group, down from 0.1% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
VIVS Sales vs. its Competitors, Q1 2026
Vivosim Labs Inc reported revenue contraction of 51.35 % year on year in Q1 2026, below its competitors' combined revenue growth of 274.37 %.
With a net margin of -7,433.33 %, Vivosim Labs Inc reported lower profitability than its competitors (-98.18 %).
Vivosim Labs Inc generated 0.02 % of the combined sales of its peer group, down from 0.14 % a year earlier.
Vivosim Labs Inc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Vivosim Labs Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Vivosim Labs Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Vivosim Labs Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Vivosim Labs Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.8% year over year, combined, vs -51.4% for Vivosim Labs Inc. Vivosim Labs Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Vivosim Labs Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Vivosim Labs Inc | No | No | No | Yes |
| Competitors combined (12) | ||||
| Similar-Size Competitors (10) | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
VIVS Stock Performance relative to its Competitors
VIVS Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Fate Therapeutics Inc | 282.9% | Outperformed |
| 2 | Brainstorm Cell Therapeutics inc | 282.9% | Outperformed |
| 3 | Aura Biosciences Inc | 282.9% | Outperformed |
| 4 | Mesoblast Limited | 282.9% | Outperformed |
| 5 | Biocardia Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Vivosim Labs Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Vivosim Labs Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Vivosim Labs Inc |
0.80 | 0.11 |
 Mesoblast Limited |
1,725.94 | 17.20 |
 Aura Biosciences Inc |
630.84 | - |
 Regenxbio Inc |
408.75 | 174.48 |
 Lineage Cell Therapeutics Inc |
269.32 | 13.08 |
 Fate Therapeutics Inc |
251.63 | 6.49 |
| SUBTOTAL | 3,462.25 | 353.96 |
Sign in to see all competitors of Vivosim Labs Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Vivosim Labs Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Vivosim Labs Inc's Competitors Named by the Company
Competitive relationships identified from Vivosim Labs Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Visikol, Inc. | Company report | 85% |
| Cellink AB | Company report | 85% |
| MatTek Incorporated | Company report | 85% |
| BICO Group AB | Company report | 85% |
Company report basis, confidence, active dates and source counts for Vivosim Labs Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Vivosim Labs Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Vivosim Labs Inc | 1 | - | - |
| Mesoblast Limited | 1,726 | 159,241 | -945,759 |
| Aura Biosciences Inc | 631 | - | -1,159,389 |
| Regenxbio Inc | 409 | 470,302 | -529,466 |
| Lineage Cell Therapeutics Inc | 269 | 169,909 | -416,948 |
| Fate Therapeutics Inc | 252 | 40,317 | -782,584 |
| PEERS TOTAL | 3,461 | 266,653 | -429,438 |
Vivosim Labs Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 158 companies in Vivosim Labs Inc's industry classification, broader than the peer set above. Market cap in millions of $.Vivosim Labs Inc ranks #154 of 158 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,370, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 260,293 | 26.21 % |
| 2 | Gilead Sciences Inc | 216,879 | 21.84 % |
| 3 | Moderna Inc | 102,835 | 10.35 % |
| 4 | Argenx Se | 61,498 | 6.19 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Mesoblast Limited | 1,234 | 5.2% |
| 10 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 154 | Vivosim Labs Inc | 1 | 0.00 % |
Market cap and industry share for the rest of Vivosim Labs Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-04.
Vivosim Labs Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 149 | Aim Immunotech Inc | 3 | -91.74 % |
| 150 | Creative Medical Technology Holdings Inc | 2 | -79.26 % |
| 151 | Curis Inc | 2 | 5.95 % |
| 152 | Nkgen Biotech Inc | 1 | - |
| 153 | Calidi Biotherapeutics Inc | 1,234 | 12.3% |
| 154 | Vivosim Labs Inc | 1 | -93.44 % |
| 155 | Sqz Biotechnologies Company | 1,234 | 12.3% |
| 156 | Green Planet Bioengineering Co Ltd | 1,234 | 12.3% |
| 157 | Silexion Therapeutics Corp | 1,234 | 12.3% |
| 158 | Mymetics Corporation | 1,234 | 12.3% |
| 159 | Windtree Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Vivosim Labs Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-04. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Vivosim Labs Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (143 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 28.3x | - |
| EV / EBITDA | - | 17.6x | - |
| P/B | 2.0x | 5.2x | -3.2x |
| Return on Equity | -6.12 % | industry aggregate | -4.60 % |
| Return on Invested Capital | - | -8.88 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Vivosim Labs Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -18.42 % | -18.20 % | - | - | - | - | - | 16.39 % |
| Operating Margin | -787.68 % | -895.13 % | - | - | - | - | - | - |
| Return on Invested Capital | -34.28 % | -37.74 % | -37.16 % | -17.02 % | -21.92 % | -74.10 % | 15.59 % | - |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Vivosim Labs Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Vivosim Labs Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.5% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Vivosim Labs Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,370 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Vivosim Labs Inc's dedicated Suppliers and Customers pages, not here.
Vivosim Labs Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Vivosim Labs Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Vivosim Labs Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-35.7% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Vivosim Labs Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Vivosim Labs Inc | 2.27 | 2.72 | - |
| Mesoblast Limited | 1.57 | 1.99 | 0.09 |
| Aura Biosciences Inc | 3.53 | 10.44 | - |
| Regenxbio Inc | 0.54 | 2.61 | - |
| Lineage Cell Therapeutics Inc | 4.19 | 5.70 | - |
| Fate Therapeutics Inc | 2.20 | 6.02 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Vivosim Labs Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Vivosim Labs Inc | Q2 2026 | -51.4 % | - |
| Mesoblast Limited | Q2 2025 | +191.4 % | - |
| Aura Biosciences Inc | Q2 2026 | - | - |
| Regenxbio Inc | Q2 2026 | +405.7 % | - |
| Lineage Cell Therapeutics Inc | Q2 2026 | -61.3 % | - |
| Fate Therapeutics Inc | Q2 2026 | +9.2 % | - |
| PEERS TOTAL | +201.2 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Vivosim Labs Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Vivosim Labs Inc | Q2 2026 | - | - |
| Mesoblast Limited | Q2 2025 | - | +150.9 % |
| Aura Biosciences Inc | Q2 2026 | - | -46.2 % |
| Regenxbio Inc | Q2 2026 | - | +94.4 % |
| Lineage Cell Therapeutics Inc | Q2 2026 | - | +671.4 % |
| Fate Therapeutics Inc | Q2 2026 | - | -94.1 % |
Vivosim Labs Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Vivosim Labs Inc | - | - | - |
| Mesoblast Limited | - | - | - |
| Aura Biosciences Inc | - | - | - |
| Regenxbio Inc | - | - | - |
| Lineage Cell Therapeutics Inc | - | - | - |
| Fate Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Vivosim Labs Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Vivosim Labs Inc | - | 7.12 |
| Mesoblast Limited | - | 100.36 |
| Aura Biosciences Inc | - | - |
| Regenxbio Inc | - | 2.34 |
| Lineage Cell Therapeutics Inc | - | 20.59 |
| Fate Therapeutics Inc | - | 38.77 |
| PEERS AVERAGE | - | 9.78 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.